Results 1 to 2 of 2

Thread: Geron Corporation CEO Thomas Okarma to Deliver Keynote Presentation At Biotech 2002

  1. #1
    Senior Member Max's Avatar
    Join Date
    Jul 2001
    Montreal,Province of Quebec, CANADA

    Geron Corporation CEO Thomas Okarma to Deliver Keynote Presentation At Biotech 2002

    Geron Corporation CEO Thomas Okarma to Deliver Keynote Presentation At Biotech 2002
    MENLO PARK, Calif.--(BW HealthWire)--May 13, 2002--Geron Corporation's (Nasdaq:GERN - News) regenerative medicine program will be featured in a keynote presentation given by Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer, at Biotech 2002 on May 20, 2002, in Research Triangle Park, N.C. The Southeast's premier life sciences industry conference, Biotech 2002 is co-hosted by the Council for Entrepreneurial Development (CED), the North Carolina Biotechnology Center (NCBC), the North Carolina Biosciences Organization (NCBIO) and the Biotechnology Industry Organization (BIO).

    Biotech 2002 organizers asked Dr. Okarma to deliver the keynote address at the conference and speak to Geron's leadership in telomerase and human embryonic stem cells (hESCs), which hold promise for the scalable production of therapeutic cells potentially useful for such diseases as diabetes, Parkinson's disease, heart failure and spinal cord injury. Dr. Okarma will discuss the production, characterization and early animal testing of therapeutic cells produced from hESCs, which include neural cells, cardiomyocytes, islets, osteoblasts, chondrocytes, hematopoietic cells, and hepatocytes. He will explain the scientific basis for the potential medical utility of hESCs and telomerase and will also address the differences between hESCs and so-called "adult stem" cells. Dr. Okarma will also provide insight into the ongoing debate surrounding therapeutic cloning.

    Geron's ties to the North Carolina biotech community include the clinical trials being conducted with the company's cancer vaccine at Duke University Medical Center and research collaborations with Duke faculty.

    Geron has been a leader in the embryonic stem cell field since 1995, when it initiated sponsored research collaborations at three university laboratories. These early funding efforts led to the successful derivation of hESCs in 1998 and the subsequent development at Geron of seven different differentiated cell types, as well as production methods for manufacturing commercial scale quantities of therapeutic cells.

    About Geron Corporation

    Geron is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron's product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer. Additional information about the company can be obtained at

    About Biotech 2002

    Biotech 2002 is the 11th Annual conference celebrating the thriving life sciences industry in North Carolina. This daylong event, scheduled for May 20, 2002 at the Sheraton Imperial Hotel in Research Triangle Park, N.C., features company exhibits as well as expert panel discussions on the industry's hottest issues, including stem cell research, biotechnology in public health, genomics challenges, the international marketplace, and life science investing. More information can be obtained at
    About CED

    The Council for Entrepreneurial Development, located in Research Triangle Park, N.C., is a private non-profit organization formed in 1984 to stimulate the creation and growth of high-impact companies in the greater Research Triangle region. CED provides education, mentoring, and capital formation resources to new and existing high growth entrepreneurs through annual conferences, seminars, workshops and monthly programs on entrepreneurial management and finance. CED is the largest entrepreneurial support organization in the nation with more than 5,000 members representing 1,200 entrepreneurial companies, financiers and professional firms. More information can be obtained at
    This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future applications of Geron Corporation's technology constitute forward-looking statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, dependence on collaborative partners, and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended March 31, 2002.


    Geron Corporation
    Laura Zobkiw, 650/473-7765

  2. #2

    I bought a couple thousand shares of this a couple days ago

    I have the feeling they are going announce something big at this upcoming meeting. Their Cancer Vaccine sounds very hopeful.

    "Life is about how you
    respond to not only the
    challenges you're dealt but
    the challenges you seek...If
    you have no goals, no
    mountains to climb, your
    soul dies".~Liz Fordred

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts